Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Allergan Aesthetics launches HArmonyCa™ with Lidocaine, its first dual-effect Hybrid Injectable


News provided by

Allergan Aesthetics, an AbbVie company

01 Apr, 2022, 07:00 GMT

Share this article

Share toX

Share this article

Share toX

---- The dual-effect Hybrid Injectable contains two active ingredients, hyaluronic acid (HA) - a well-known ingredient found in facial fillers1 - and calcium hydroxyapatite (CaHA) which is known to help stimulate collagen production2,3 ---

---- In one single injection HArmonyCaTM offers the potential of an immediate lift4§§ effect from HA and sustained collagen stimulation from CaHA5††, and may be suitable for people exhibiting signs of ageing2----

---- Over 90% [91.6%, N=162] of patients reported improvement in general appearance of facial areas following treatment with HArmonyCaTM6§# ----

MONACO, April 1, 2022 /PRNewswire/ -- Today, at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco Allergan Aesthetics, an AbbVie Company, a global leader in medical aesthetic treatments and maker of Juvéderm® facial fillers and CoolSculpting® body contouring treatment, announces its entry into the category of Hybrid Injectables with the launch of HArmonyCa™ with Lidocaine.2

Exploring new possibilities

As market leader Allergan Aesthetics looks to further develop this exciting category of Hybrid Injectables by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) - in one injection.2 The treatment may offer the improvement of an immediate lift4§§ from HA, plus a sustained lifting effect from CaHA causing new collagen production.5†† In a late follow- up satisfaction cohort (N=45) of a post marketing clinical follow up of safety and performance of HArmonyCaTM (N=162), a majority of patients reported a high user satisfaction (mean 4.1 out of 5) for overall satisfaction, and likeliness to repeat similar treatment up to 19 months after treatment with HArmonyCaTM.6 §||||

The science

HArmonyCaTM is intended for facial soft tissue augmentation via injection into deep dermal and sub-dermal layers.2 It is a dual-effect Hybrid Injectable containing:

  • Cross-linked HA gel, which may provide an immediate lifting effect that is mouldable,7 allowing a qualified aesthetic practitioner to adjust the implant shape following administration2,8 
  • CaHA microspheres, which support the body's own collagen production by inducing the formation of collagen fibres2,3,9

The hyaluronic acid particles work deep within the skin, where they help plump it for an immediate lifting effect,7† while the CaHA microspheres work to support the body's own collagen production, so new collagen fibres start to grow.3,9 Newly formed collagen fibres may be present as early as one week following treatment.5††

Dr. André Braz, Brazil comments, "The texture of the skin changes as we age, and laxity or sagging can become a problem. Hyaluronic acid may help by providing an immediate lift, while calcium hydroxyapatite may be used to improve facial architecture and is associated with a sustained lifting effect from new collagen production. The combination of HA and CaHA in one HArmonyCa™ injection is an exciting new option for patients and aesthetic practitioners alike."

The multi-dimensional needs of the ageing face 
Loss of facial volume and changes to the soft-tissue are two of the most common signs of ageing.10,11,12 In global  research13 exploring people's attitudes to ageing and aesthetics, almost all respondents (96%, N=12,360)13 had a concern about an area of their face, with more than a third stating they were concerned about the quality of their skin (40%, N=12,360)13 or its loss of tightness (39%, N=12,360).13  

When asked if they would consider a non-surgical aesthetic treatment  that stimulates their body to increase its production of collagen in the skin two thirds of people said they would (67%, N=12,360).13 

Carrie Strom, SVP, AbbVie and President, Global Allergan Aesthetics notes, "The launch of HArmonyCa™ with Lidocaine represents Allergan Aesthetics' continued commitment to providing the latest innovations, treatments and possible outcomes for patients. We are driven by leading-edge science and are continually looking to diversify our portfolio by pushing the boundaries of what non-surgical treatments can offer. We are delighted to introduce our first Hybrid Injectable to market and believe its potential to offer immediate lift from hyaluronic acid with the lasting collagen stimulation associated with calcium hydroxyapatite may answer some of the multi-dimensional needs of ageing skin."

The evidence 
Significant clinical improvements have been demonstrated with HArmonyCaTM with Lidocaine from baseline to subsequent follow up in a recent clinical study (N=162), with:6§

  •  86% of 85 treated regions among 48 patients6§|| showing clinically significant improvement
  • 91.6% of patients registering an improvement in general appearance of facial areas treated with HArmonyCaTM 6#§

HArmonyCaTM has been clinically shown to deliver a low risk-benefit profile.6 In a post marketing clinical analysis of HArmonyCaTM (N=162) commonly occurring side effects (erythema, swelling, pain, tenderness and itching) were manageable and self- limiting.6 ## A full list of side-effects, contraindications, warnings and precautions can be found in the HArmonyCaTM Instructions For Use manual.2

Training and education are an integral part of the Allergan Aesthetics offering. Allergan Aesthetics trains over 75,000 medical professionals around the world each year and Allergan will provide a range of in-person and virtual training packages to support medical professionals who wish to offer HArmonyCa™ with Lidocaine to their patients.

HArmonyCa™ was originally developed in Israel and has been commercially available in Brazil, Israel and Ukraine. Having now secured a CE mark, it is being launched across Europe and in select EEMEA countries. Allergan Aesthetics will continue to explore and work with appropriate regulatory authorities around the world to make HArmonyCa™ more widely available in the future.

Allergan Aesthetics is known for its leading filler range and as the company behind the world's number one brand of HA facial fillers, JUVÉDERM®.14¶¶ HArmonyCa™ with Lidocaine is the newest addition to its growing aesthetics portfolio and represents AbbVie's commitment to investing in the future of the aesthetics market.

For more information please contact your local Allergan Aesthetics office or representative.

Notes to Editors

About Allergan Aesthetics 
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes dermal filler, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.co.uk 

About AbbVie 
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Contact(s)

International Media: 
Karen Dennehy 
Director, Communications & Public Relations, International Brands, Allergan Aesthetics 
+44 7824 017 950

UK Media: 
Stacey Brazier 
Head of Communications & Public Relations, UK, Allergan Aesthetics 
Stacey.Brazier@allergan.com  
+44 7879 435 640

Footnotes:

HArmonyCaTM with Lidocaine is referred to as HArmonyCaTM throughout 
* Online interviews completed by over 12,000 'aesthetically aware' 25-64-year-old women and men across 15 countries between July 14th to August 4th 2021. Funded by Allergan13 
† Results derived from an animal model study comparing fillers7  
§ A post marketing clinical follow up of safety and performance of HArmonyCaTM (N=162)6 
|| Performance evaluation using the Lemperle Scale6 
# Performance evaluation using the Global Aesthetic Improvement Scale6 
**With CaHA collagen formation can last up to 12 months3 
†† Results from a pre-clinical animal study of HArmonyCaTM with results demonstrated over 8 weeks5 
§§ Results from a pre-clinical animal study of HArmonyCaTM with results demonstrated over 12 weeks4 
|||| Performance evaluation using the 5-point Likert Scale User Satisfaction Questionnaire6 
¶¶ Based on healthcare professional tracking market research, from over 1,000 healthcare professionals in the largest 13 aesthetic markets worldwide14  
## In a post-marketing clinical analysis of HArmonyCa™ (N=162), one unrelated serious adverse event (AE) was reported and one AE required medical intervention due to material migration into the lips and over correction6

References

1 De Boulle K, et. al. Dermatol Surg. 2013 Dec;39(12):1758-66. 
2 Allergan Aesthetics. HArmonyCaTM Lidocaine IFU. M032 V01. 2021. 
3 Gonzaga da Cunha M, et al. Surg Cosmet Dermatol. 2020;12:109–17. 
4 Allergan Aesthetics. Data on File. HArmonyCaTM Lidocaine INT-HAR-2150036. Lift capacity. July 2021. 
5 Allergan Aesthetics. Data on File. HArmonyCaTM Lidocaine INT-HAR-2150040. Collagen stimulation. July 2021. 
6 Allergan Aesthetics. Data on File. INT-HAR-2150007.HArmonyCaTM. Clinical Study Report. April 2021. 
7 Hee C, et al. Dermatol Surg. 2015;41:S373–381. 
8 Lipko-Godlewska S, et al. J Cosmet Dermatol. 2021;14:169–178. 
9 Zerbinati N, Calligaro A. Clin Cosmet Investig Dermatol. 2018;11:29–35. 
10 Kahn DM, Shaw RB. Facial Plast Surg. 2010;26:350–355. 
11 Swift A, et al. Aesthet Surg J. 2020;sjaa339. 
12 Coleman SR, Grover R. Aesthet SurgJ. 2006;26:S4-S9. 
13 Consumer Beauty Insights Study 2021 - REF-83962 
14 Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM®, the world's leading brand of hyaluronic acid facial fillers. Feb 2019.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.